Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1
Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
The investigators will treat 50 patients with cirrhosis due to hepatitis C genotype 1, with
sofosbuvir 400 mg daily, ledipasvir 90 mg daily and weight-based ribavirin (1000 mg/d if <75
kg, 1200 mg/d if >75 kg, divided in two daily doses) for 12 weeks and calculate the sustained
viral response rate at 12 weeks.